All patients with PGx panel testing n (%) Patients with specific drug-gene based indication n (%) Patients with PGx screening n (%)
n (%) 135 (100) 102 (75.5) 33 (24.5)
Age: median (range) 68 (25 - 92) 70 (25 - 92) 58 (30 - 83)
<60 48 (35.6) 30 (29.4) 18 (54.6)
61 - 70 25 (18.5) 22 (21.6) 3 (9.1)
71 - 80 41 (30.4) 33 (32.4) 8 (24.2)
>80 21 (15.6) 17 (16.7) 4 (12.1)
Sex
male 81 (60) 56 (54.9) 25 (75.8)
female 54 (40) 46 (45.1) 8 (24.2)
eGFR < 60 ml/min1 19 (14.1) 16 (15.7 ) 3 (9.1)
Indication PGx panel test
Clopidogrel 60 (44.4) 60 (58.8) na
Tamoxifen 15 (11.1) 15 (14.7) na
Polypsychopharmacotherapy 9 (6.7) 9 (8.8) na
Opioids 7 (5.2) 7 (6.9) na
Statins 6 (4.4) 6 (5.9) na
Phenprocoumon 2 (1.5) 2 (1.9) na
Chemotherapy 2 (1.5) 2 (1.9) na
PPI 1 (0.7) 1 (0.9) na
Pharmacotherapy
Number of drugs: median (range)2 6 (0 - 19) 6 (0 - 19) 3 (0 - 14)
Aspirin 43 (31.9) 38 (37.3) 5 (15.2)
Clopidogrel 48 (35.6) 48 (47.1) 0 (0)
Prasugrel or Ticagrelor 1 (0.7) 1 (0.9) 0 (0)
Coumarines or NOAC 25 (18.5) 22 (21.6) 3 (9.1)
Beta blockers 44 (32.6) 35 (34.3) 9 (27.3)
ACE or ARB 60 (44.4) 48 (47.1) 12 (36.4)
CCB 20 (14.8) 16 (15.7) 4 (12.1)
Diuretics 34 (25.2) 28 (27.5) 6 (18.2)
PPI 45 (33.3) 40 (39.2) 5 (15.2)
Cholesterol lowering drugs 55 (40.7) 48 (47.1) 7 (21.2)
NSAR 12 (8.9) 11 (10.8) 1 (3.0)
Opioids 17 (12.6) 14 (13.7) 3 (9.1)
Uric acid lowering drugs 5 (3.7) 3 (2.9) 2 (6.1)
Benzodiazepines 18 (13.3) 14 (13.7) 4 (12.1)
Antidepressants 28 (20.7) 24 (23.5) 4 (12.1)
Antipsychotics 10 (7.4) 9 (8.8) 1 (3.0)
Antiepileptics 9 (6.7) 8 (7.8) 1 (3.0)
Antidiabetics 22 (16.3) 17 (16.7) 5 (15.2)
Tamoxifen 12 (8.9) 12 (11.8) 0 (0)
CYP2C19 Inhibitor3 11 (8.2) 10 (9.8) 1 (3.0)
CYP2D6 Inhibitor3 26 (19.3) 20 (19.6) 6 (18.2)